Pharmaceuticals

BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca's portfolio

- Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery platform and experimentally validated by AstraZeneca - Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca'...

2021-12-15 16:00 1663

Endurance Longevity Signed Exclusive Licence Agreement to Commercialise Fortacin™ in the Israeli and Balkan regions

HONG KONG, Dec. 15, 2021 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) announced that Plethora Solutions Limited (Solutions), a wholly owned subsidiary of the Company has entered into an exclusive ...

2021-12-15 15:01 3440

Red Seal brings New Zealand's #1 best-selling herbal and mineral toothpaste to Pharmaca Integrative Pharmacies, USA

AUCKLAND, New Zealand, Dec. 14, 2021 /PRNewswire/ -- Wednesday 14 December, 2021 , Red Seal is proud to announce their herbal and mineral toothpastes are now conveniently available at all 28 distinguished Pharmaca stores nationwide.  www.redseal.global/usa Pharmaca...

2021-12-15 10:41 2358

RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021

YANTAI, China, Dec. 15, 2021 /PRNewswire/ -- To celebrate World Strengthened Immunity Day, RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, reiterated its commitment to discovering, developing, and producing best-in-class biological drugs for autoimmune diseases, to create c...

2021-12-15 09:35 4103

Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea

SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet nee...

2021-12-15 08:00 4834

ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety

SUZHOU, China, and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from three ...

2021-12-14 22:04 3180

ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses

SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from six st...

2021-12-14 22:04 2861

Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting

SHANGHAI and HONG KONG, Dec. 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...

2021-12-14 18:00 3979

CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd

MELBOURNE, Australia and ST. GALLEN, Switzerland, Dec. 14, 2021 /PRNewswire/ -- CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd - Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021 - Expands CSL's leadership across an attractive portfolio ...

2021-12-14 14:59 3520

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

Companies will collaborate on manufacturing and research and development for future indications, and will commercialize Gadopiclenol independently under separate brands Gadopiclenol is a next-generation, macrocyclic contrast agent with high-relaxivity, intended to improve lesion detection and vi...

2021-12-14 14:00 3381

Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea

CAMBRIDGE, Mass. and INCHEON, South Korea, Dec. 14, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that the Ministry of Food and Drug Safety of Korea (MFDS) has issued a marketing authorization for Sp...

2021-12-14 13:34 2534

Cargene Closes a US$19.2M Pre-A Round Led by BioTrack Capital

SINGAPORE and SHANGHAI and BOSTON, Dec. 14, 2021 /PRNewswire/ -- Cargene Biopharma Inc.  ("Cargene") announced today the close of an over-subscribedUS$19.2 million pre-Series A funding round. The financing was led by BioTrack Capital, with participation from Hyfinity Inv...

2021-12-14 09:00 5184

Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy

INCHEON, South Korea, Dec. 13, 2021 /PRNewswire/ -- Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN). The partnership is based on an...

2021-12-14 08:55 2702

Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3Kδ inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma

SAN FRANCISCO and SUZHOU, China, Dec. 14, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2021-12-14 08:00 3932

Old Drugs Given New Life: Acura NanoMedicine Inc. Upgrades Existing Drugs Providing a More Efficient the Treatment for Cancer

TAIPEI, Dec. 13, 2021 /PRNewswire/ -- Taiwanese company Acura NanoMedicine Inc ( https://www.acura-nanomed.com/ ), an award-winning health tech and biomedicine company, announces a groundbreaking nanotech-based solution to reduce instances of drug resistance and giv...

2021-12-14 00:00 2498

CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting

SHANGHAI, Dec. 13, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announces that at the 2021 American Society of Hematology ("ASH") Annual ...

2021-12-13 20:00 6224

Cleverin, Top Made-in-Japan Airborne Disinfectant Brand by Taiko Pharmaceutical, Accelerating Its Business Expansion in Mexico through Acquisition of Its Mexican Distributor

OSAKA, Japan, Dec. 13, 2021 /PRNewswire/ -- Taiko Pharmaceutical Co., Ltd. (hereinafter Taiko), based inOsaka, Japan, has announced that it fully acquired Mexican distributor Torishi S.A. de C.V. inNovember 2021 in order to expand the infection control business. Taiko has worked with the excellen...

2021-12-13 14:00 3509

IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting

SAN JOSE and SAN FRANCISCO and NANJING, China, Dec. 12, 2021 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing innovative medicines and Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-cla...

2021-12-13 12:14 2799

Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvements in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate Safety profile was favorable and consis...

2021-12-13 09:03 3657

Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other ma...

2021-12-13 08:00 4346
1 ... 322323324325326327328 ... 346